This study is looking at how a blood test called circulating tumor DNA (ctDNA) can help doctors understand the risk of breast cancer coming back after surgery. ctDNA is a sign of minimal residual disease (MRD), meaning a very small amount of cancer cells might still be present. Researchers want to see if detecting ctDNA in patients with early-stage breast cancer that has spread to 1-3 lymph nodes can predict who is at higher risk of recurrence. This study will also include a specific group of African American/Black women, as they are often underrepresented in this type of research. The goal is to improve treatment plans by using ctDNA results to guide decisions about therapies like radiation and chemotherapy. You would have blood collected for ctDNA testing at the start of the study and every three months afterward.

Study design

This is an interventional study with a planned enrollment of 100 participants. The phase is not specified.

What's involved

You would have blood collected for ctDNA testing at the time of enrollment (before starting other treatments) and every three months thereafter.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint measures ctDNA positivity at baseline, but the study will correlate results with recurrence-free and overall survival, implying ongoing follow-up.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.